Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | APAF1 | O14727 | 1/20 | 0.70 |
| ▸ | RECQL | P46063 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | MPO | P05164 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30912052 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL29361050 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL29556806 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL891879 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL578606 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL30833074 | 0.89 | SMN1; SMN2 (0.81) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| Cystine SCHEMBL30036693 | 0.87 | SMN1; SMN2 (0.76) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL4987528 | 0.87 | SMN1; SMN2 (0.76) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL9449541 | 0.87 | SMN1; SMN2 (0.77) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL29388323 | 0.86 | SMN1; SMN2 (0.74) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040053382-A1 | Production of alpha-hydroxy-carboxylic acids using a coupled enzyme system | EXCELSYN MOLECULAR DEVELOPMENT LIMITED (GB) | 2004-03-18 | — | — | US | claimed |
| EP-1326993-A2 | PRODUCTION OF g(a)-HYDROXY-CARBOXYLIC ACIDS USING A COUPLED ENZYME SYSTEM | PCBU Services, Inc. (US) | 2003-07-16 | — | — | EP | claimed |
| WO-2002033110-A2 | PRODUCTION OF α-HYDROXY-CARBOXYLIC ACIDS USING A COUPLED ENZYME SYSTEM | PCBU SERVICES, INC. (US) | 2002-04-25 | — | — | WO | claimed |
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| WO-2022078416-A1 | NOVEL GLUTAMINE ANALOGS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022078462-A1 | NOVEL GLUTAMINE ANALOGS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| WO-2018204764-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION (US) | 2018-11-08 | — | — | WO | disclosed |
| US-20120208244-A1 | METHOD FOR PRODUCING MONATIN | AJINOMOTO CO., INC. (JP) | 2012-08-16 | — | — | US | disclosed |
| US-8067398-B2 | Biodegradable polymers having a pre-determined chirality | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2011-11-29 | — | — | US | disclosed |
| US-6921758-B2 | Amino acid derivatives | ASTRAZENECA AB (SE) | 2005-07-26 | — | — | US | disclosed |
| US-20040087647-A1 | NEW AMINO ACID DERIVATIVES | ASTRAZENECA AB | 2004-05-06 | — | — | US | disclosed |
| US-6617320-B2 | Protease inhibitor; anticoagulants | ASTRAZENECA AB (SE) | 2003-09-09 | — | — | US | disclosed |
| EP-0836615-B1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | ASTRAZENECA AB (SE) | 2003-04-23 | — | — | EP | disclosed |
| US-20020042396-A1 | Amino acid derivatives | ASTRA AB | 2002-04-11 | — | — | US | disclosed |
| US-6337343-B1 | TREATMENT OF THROMBOSIS WITH ANTICOAGULANTS | ASTRAZENECA AB (SE) | 2002-01-08 | — | — | US | disclosed |
| US-6051568-A | Thrombin inhibitors, their preparation and use | ASTRA AKTIEBOLAG (SE) | 2000-04-18 | — | — | US | disclosed |
| EP-0836615-A1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | Astra Aktiebolag (SE) | 1998-04-22 | — | — | EP | disclosed |
| WO-1997002284-A1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | ASTRA AKTIEBOLAG (SE) | 1997-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399297-A1 | Novel Glutamine Analogs | GLUL, GATD3, GLS | SMN1; SMN2 3812/4885KDM4E 1022/4885MAPT 2809/4885 |
| US-20020042396-A1 | Amino acid derivatives | F2, SERPINC1, ARGLU1 | SMN1; SMN2 4625/4885KDM4E 3696/4885MAPT 4713/4885 |
| US-20040087647-A1 | NEW AMINO ACID DERIVATIVES | F2, ANPEP, PEPD | SMN1; SMN2 4577/4885KDM4E 3481/4885MAPT 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.